芪参复康胶囊对重度抑郁症患者智力及事件相关电位的影响

The Effect of Qishenfukang Capsules on Intelligence and Event-related Potentials Change of Major Depressive Disorder

目的探讨中药芪参复康胶囊治疗重度抑郁症患者前后的临床症状、智力、P3潜伏期和波幅的变化。方法将45例重度抑郁症患者随机分为芪参复康胶囊治疗组(试验组22例)及氟西汀治疗组(氟西汀组23例),对两组在治疗前和治疗后8周评定17项汉密尔顿抑郁量表(HAMD)、韦氏成人智力及进行P300检查,并与22名健康志愿者(对照组)进行比较。结果①治疗后试验组和氟西汀组HAMD得分均显著下降(t=6.03,5.12;P<0.05);②与治疗前相比,试验组和氟西汀组治疗后言语智商、操作智商和总智商的成绩均显著升高(t=4.01,5.36,4.79,3.52,3.90,4.04;P<0.05)。治疗前与对照组相比,试验组和氟西汀组言语智商、操作智商和总智商的成绩均显著降低(t=4.25,4.83,4.42,4.22,4.91,4.30;P<0.05);治疗后试验组和氟西汀组操作智商均仍低于对照组(t=2.02,2.51,P<0.05),言语智商和总智商分与对照组相当;治疗后试验组操作智商显著高于氟西汀组(t=2.10,P<0.05),言语智商差异不显著;③与治疗前相比,试验组和氟西汀组治疗后P3潜伏期均显著缩短(F=4.66,4.20;P<0.05)、波幅均显著升高(F=5.88,5.47;P<0.05)。治疗前与对照组相比,试验组、氟西汀组P3潜伏期均延迟(F=3.90,3.89;P<0.05),波幅均降低(F=4.13,4.10;P<0.05);治疗后,试验组P3潜伏期、波幅均差异不显著;氟西汀组P3潜伏期差异不显著,P3波幅仍偏低(F=2.03,P<0.05)。结论芪参复康胶囊治疗抑郁症患者后临床症状明显缓解、认知功能有明显改善,其中智力改善疗效肯定,芪参复康胶囊改善操作智商优于氟西汀。

Objective To explore the effect of Qishenfukang capsules on clinical symptom intelligence,P3 latency and amplitucle of major depressive disorder.Methods A total of 45 patients with major depressive disorders were given Qishenfukang capsules group（n=22）or Fluoxetine（n=23）group for 8 weeks and their conditions were evaluated by using 17-item Hamilton Depression Scale（HAMD）.The cognition function was determined by using Wechsler adult intelligence scale（WAIS-RC）,and by P300 change before and after treatment.Another 22 healthy subjects were involved as controls and they were given simultaneously the same tests.Results ①The HAMD scores of Qishen fukang and Fluoxetine groups were decreased significantly[（29.1±5.1）vs.（10.1±3.2）,t=6.03,P0.05;（29.0±4.5）vs.（12.3±3.4）,t=5.12,P0.05].②Compared with prior-treatment,verbal IQ,performance IQ and total IQ scores were significantly higher in the Qishenfukang and Fluoxetine groups post-treatment（t=4.01,5.36,4.79,3.52,3.90,4.04;P0.05）.Compared with the controls,verbal IQ,performance IQ and total IQ scores were significantly lower in the Qishenfukang and Fluoxetine groups before treatment（t=4.25,4.83,4.42,4.22,4.91,4.30;P0.05）;performance IQ was still significantly lower（t=2.02,2.51;P0.05）,verbal IQ and total IQ points were not significant difference in major depressive disorder post-treatment（P0.05）.And no difference on verbal IQ was found in the Qishenfukang and Fluoxetine groups,performance IQ in the Qishenfukang group was significant higher than that in the Fluoxetine groups（t=2.10,P0.05）.③Compared with prior-treatment,the P3 latency was shortened（F=4.66,4.20;P0.05）while the amplitude was prolonged in the Qishenfukang and Fluoxetine groups post-treatment（F=5.88,5.47;P0.05）.Compared with the controls,the P3 latency was shortened（F=3.90,3.89;P0.05）while the amplitude was prolonged in the Qishenfukang and Fluoxetine groups prior-treatment（F=4.13,4.10;P0.05）.The P3 latency and amplitude were no differences in the Qishenfukang group post-treatment（P0.05）.The P3 amplitude were still lower in the Fluoxetine group post-treatment（F=2.03,P0.05）while no difference was found on the P3 latency（P0.05）.Conclusion The clinical symptoms,cognitive function and memory function have improved in major depressive disorder after medication with Qishenfukang capsules.To a certain extent,Qishenfukang capsules is especially superior to Fluoxetine on improving performance IQ.